Literature DB >> 12360404

Human p14(Arf): an exquisite sensor of morphological changes and of short-lived perturbations in cell cycle and in nucleolar function.

Thérèse David-Pfeuty1, Yolande Nouvian-Dooghe.   

Abstract

The human Ink4a/Arf tumor suppressor locus encodes two distinct products: p16(Ink4a) which prevents phosphorylation and inactivation of the retinoblastoma protein and, p14(Arf), a nucleolar protein which activates the function of the tumor suppressor p53 protein in the nucleoplasm in response to oncogenic stimulation through an as yet ill-defined mechanism. Here we show that the level of endogenous p14(Arf) and its balance between the nucleolus and the nucleoplasm in HeLa cells are exquisitely sensitive to changes in cell morphology and to short-lived perturbations in cell cycle and in nucleolar function such as those induced by the cyclin-dependent kinase inhibitor, roscovitine, and the casein kinase II and RNA synthesis inhibitor, DRB. Most remarkably, whereas p14(Arf) predominantly concentrates in the nucleolus of interphase cells and transiently disappears between metaphase and early G1 under normal growth conditions, it massively and reversibly accumulates in the nucleoplasm of postmitotic and S-phase cells upon short-term treatment with roscovitine and, at a lesser extent, DRB. In line with the fact that the nuclear level of p53 reaches a peak between mid-G1 and the G1/S border in p53-expressor cells which lack Arf expression, these results provide a clue that, in p53+/Arf+ cells, Arf proteins might serve both to speed and to amplify p53-mediated responses in conditions and cell cycle periods in which the mechanisms involved in p53 stabilization and activation are not fully operational. They further suggest that human endogenous p14(Arf) might activate p53 pathways in physiologic situations by acting inside the nucleoplasm, especially when normal cell cycle progression and nucleolar function are compromised.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12360404     DOI: 10.1038/sj.onc.1205871

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

Review 1.  The moving parts of the nucleolus.

Authors:  M O J Olson; Miroslav Dundr
Journal:  Histochem Cell Biol       Date:  2005-03-02       Impact factor: 4.304

2.  A novel ARF-binding protein (LZAP) alters ARF regulation of HDM2.

Authors:  Jialiang Wang; Xiaping He; Ying Luo; Wendell G Yarbrough
Journal:  Biochem J       Date:  2006-01-15       Impact factor: 3.857

Review 3.  DNA damage, p14ARF, nucleophosmin (NPM/B23), and cancer.

Authors:  Ruth A Gjerset
Journal:  J Mol Histol       Date:  2006-07-20       Impact factor: 2.611

4.  Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.

Authors:  Chandrashekhar Korgaonkar; Jussara Hagen; Van Tompkins; April A Frazier; Chantal Allamargot; Frederick W Quelle; Dawn E Quelle
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

Review 5.  Therapeutic targets in the ARF tumor suppressor pathway.

Authors:  Anthony J Saporita; Leonard B Maggi; Anthony J Apicelli; Jason D Weber
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

6.  Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells.

Authors:  Sandeep S Negi; Patrick Brown
Journal:  Oncotarget       Date:  2015-10-27

7.  Nucleolar sequestration of RelA (p65) regulates NF-kappaB-driven transcription and apoptosis.

Authors:  Lesley A Stark; Malcolm G Dunlop
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.